Vijayakumar Shilpa, Shah Nishant R
Division of Cardiology, Department of Medicine, Alpert Medical School of Brown University, Providence, RI 02903, USA.
Rev Cardiovasc Med. 2022 Aug 24;23(9):293. doi: 10.31083/j.rcm2309293. eCollection 2022 Sep.
Patients presenting with chest pain and related symptoms account for over 6 million emergency department (ED) visits in the United States annually. However, less than 5% of these patients are ultimately diagnosed with acute coronary syndrome (ACS). ED clinicians face the diagnostic challenge of promptly identifying and treating these high-risk patients amidst the overwhelming majority of lower-risk patients for whom further testing and/or treatment is either unnecessary or non-urgent. To assist with and expedite risk stratification and decision-making in this challenging clinical scenario, diagnostic tools like clinical risk scores and high-sensitivity serum biomarkers have been incorporated into care algorithms within the ED. In this narrative review, we discuss how these tools impact the appropriate use of cardiovascular imaging in the initial assessment of patients presenting to the ED with possible ACS.
在美国,每年因胸痛及相关症状就诊于急诊科(ED)的患者超过600万例。然而,这些患者中最终被诊断为急性冠状动脉综合征(ACS)的不到5%。急诊科临床医生面临着诊断挑战,即在绝大多数低风险患者中迅速识别和治疗这些高风险患者,而对于这些低风险患者,进一步检查和/或治疗要么不必要,要么不紧急。为了在这一具有挑战性的临床场景中协助并加快风险分层和决策制定,临床风险评分和高敏血清生物标志物等诊断工具已被纳入急诊科的护理算法中。在这篇叙述性综述中,我们讨论了这些工具如何影响对可能患有ACS而就诊于急诊科的患者进行初始评估时心血管成像的合理使用。